Brand strategy: Novo Nordisk becomes Novo: a shorter name, a bigger promise

Novo Nordisk is rebranding as Novo, dropping “Nordisk” from its day-to-day corporate identity. More than a cosmetic refresh, the move appears to reposition the Danish pharmaceutical company as a broader health brand.

The legal name Novo Nordisk will remain, but Novo will be used in everyday communications. Even the familiar Apis bull in the logo is being turned around, symbolising a new direction.

From a brand-strategy perspective, the shorter name is simpler, more international and potentially more consumer-friendly — much as Eli Lilly increasingly presents itself simply as Lilly.

But something is also lost. “Nordisk” means Nordic or Scandinavian and anchors the company in its Northern European heritage. What remains is “Novo”: a far more generic word, already present in thousands of registered trademarks and derivatives. And the name itself — suggesting “new” or “anew” — raises another question.

What happens when this implicit idea of newness starts appearing across a portfolio containing medicines that have been on the market for years? Rather than modernising them, the Novo masterbrand could create an intriguing tension between the promise of renewal and the reality of an established pharmaceutical portfolio.

But there is a downside: Novo Nordisk is highly distinctive, whereas “Novo” is a much more generic name, potentially making differentiation and trademark ownership more challenging.

The more significant change, however, may be the new brand promise: “Lasting health starts now.”

The language moves Novo beyond the traditional pharmaceutical territory of treating disease. “Lasting health” evokes prevention, longevity and healthspan — a shift from sickness towards staying healthy over time. It potentially gives Novo a much broader space in which to build its future business.

But it is also a remarkably ambitious promise for a pharmaceutical company. Medicines can treat diseases, reduce risks and improve defined clinical outcomes. Can a pharmaceutical company credibly promise “lasting health”?

There is a regulatory nuance. As a corporate slogan, the phrase is not automatically a medicinal claim. But when used in connection with prescription-drug promotion, such broad health language could raise questions about substantiation and whether it implies benefits beyond a product’s approved indication.

That leaves Novo with an interesting brand challenge: the company is making its name smaller while making its promise considerably bigger. Whether “lasting health” becomes a credible new territory for Novo may ultimately determine whether this is simply a rebrand — or the beginning of a much broader repositioning.

The Novo trademark and logo are owned and registered by Novo Nordisk